GASTRIC AND ESOPHAGEAL CANCER DRUGS MARKET ANALYSIS

Gastric And Esophageal Cancer Drugs MarketSize and Trends

Gastric and Esophageal Cancer Drugs Market- Trends

Increasing number of cancer drugs in pipeline studies and rising involvement of key players for development of cancer treatment are expected to propel gastric and esophageal cancer drugs market growth. For instance, in April 2016, Centre Hospitalier Universitaire de Besancon, initiated Phase 1 and Phase 2 clinical trial for Carboplatin to determine the maximum tolerated dose (MTD) and recommended doses for phase II (RP2D) by considering the treatment scheme of Dutch study for chemotherapy and radiotherapy. The study is conducted in elderly patients with esophagus cancer. Carboplatin is an anticancer chemotherapy drug from the alkylating agent category. The study is estimated to complete by April 2024.

Moreover, in February 2017, Henan Cancer Hospital in collaboration with Jiangsu HengRui Medicine Co., Ltd., initiated Phase 2 exploratory clinical trial to evaluate the efficacy of Apatinib in the treatment of advanced esophagus cancer. Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2).

However, the high cost of therapy for the treatment of gastric and esophageal cancers is expected to restrain market growth. For instance, as per the report published in Healthday in 2013, cancer patients paid US$ 207,000 a year for the treatment and medications while in 1995 the cost was US$ 54,100 a year.